Canopy Growth (CGC) Asset Writedowns and Impairment (2020 - 2023)
Canopy Growth (CGC) posted Asset Writedowns and Impairment of $7.9 million for Q2 2023, down 97.14% sequentially from $275.7 million in Q1 2023, and down 99.42% YoY from $1.4 billion in Q2 2022.
Canopy Growth (CGC) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends
Canopy Growth has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $7.9 million in Q2 2023.
- Quarterly Asset Writedowns and Impairment fell 99.42% year-over-year to $7.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $379.0 million (down 75.59% YoY) and the FY2023 annual result came in at $1.6 billion, up 526.97% from the prior year.
- Asset Writedowns and Impairment slipped to $7.9 million in Q2 2023 per CGC's latest filing, from $275.7 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $1.4 billion in Q2 2022 and troughed at -$809503.1 in Q3 2021.
- A 4-year average of $209.4 million and a median of $76.3 million in 2021 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment jumped 10927.04% in 2022, then tumbled 99.42% in 2023.
- Over 4 years, Asset Writedowns and Impairment stood at $228.7 million in 2020, then slumped by 88.71% to $25.8 million in 2021, then plunged by 69.77% to $7.8 million in 2022, then grew by 0.88% to $7.9 million in 2023.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $7.9 million, $275.7 million, and $7.8 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Canopy Growth | 434.93 Mn | 187.92 Mn | 16.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 7.88 Mn |
| Jun 30, 2023 | 7.88 Mn |
| Mar 31, 2023 | 275.71 Mn |
| Mar 31, 2023 | 275.71 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Sep 30, 2022 | 87.65 Mn |
| Sep 30, 2022 | 87.65 Mn |
| Jun 30, 2022 | 1.35 Bn |
| Jun 30, 2022 | 1.35 Bn |
| Mar 31, 2022 | 173.45 Mn |
| Mar 31, 2022 | 173.45 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Sep 30, 2021 | -809,503.09 |
| Sep 30, 2021 | -809,503.09 |
| Jun 30, 2021 | 66.47 Mn |
| Jun 30, 2021 | 66.47 Mn |
| Mar 31, 2021 | 76.32 Mn |
| Mar 31, 2021 | 76.32 Mn |